|
1
|
Sharma S, Ksheersagar P and Sharma P:
Diagnosis and treatment of bladder cancer. Am Fam Physician.
80:717–723. 2009.PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Van Tilborg AA, Bangma CH and Zwarthoff
EC: Bladder cancer biomarkers and their role in surveillance and
screening. Int J Urol. 16:23–30. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Giuliani L, Giberti C, Martorana G,
Bonamini A, Natta GD and Rovida S: Results of radical cystectomy
for primary bladder cancer. Retrospective study of more than 200
cases. Urology. 26:243–248. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pagano F, Bassi P, Galetti TP, Meneghini
A, Milani C, Artibani W and Garbeglio A: Results of contemporary
radical cystectomy for invasive bladder cancer: A
clinicopathological study with an emphasis on the inadequacy of the
tumor, nodes and metastases classification. The J Urol. 145:45–50.
1991.PubMed/NCBI
|
|
6
|
Xiong L, Edwards CK III and Zhou L: The
biological function and clinical utilization of CD147 in human
diseases: A review of the current scientific literature. Int J Mol
Sci. 15:17411–17441. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhu S, Li Y, Zhang Y, Wang X, Gong L, Han
X, Yao L, Lan M and Zhang W: Expression and clinical implications
of HAb18G/CD147 in hepatocellular carcinoma. Hepatol Res.
45:97–106. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xu J, Xu HY, Zhang Q, Song F, Jiang JL,
Yang XM, Mi L, Wen N, Tian R, Wang L, et al: HAb18G/CD147 functions
in invasion and metastasis of hepatocellular carcinoma. Mol Cancer
Res. 5:605–614. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xu XY, Lin N, Li YM, Zhi C and Shen H:
Expression of HAb18G/CD147 and its localization correlate with the
progression and poor prognosis of non-small cell lung cancer.
Pathol Res Pract. 209:345–352. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bhagirath D, Abrol N, Khan R, Sharma M,
Seth A and Sharma A: Expression of CD147, BIGH3 and Stathmin and
their potential role as diagnostic marker in patients with
urothelial carcinoma of the bladder. Clin Chim Acta. 413:1641–1646.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bian H, Zheng JS, Nan G, Li R, Chen C, Hu
CX, Zhang Y, Sun B, Wang XL, Cui SC, et al: Randomized trial of
[131I] metuximab in treatment of hepatocellular carcinoma after
percutaneous radiofrequency ablation. J Natl Cancer Inst.
106:2392014. View Article : Google Scholar
|
|
12
|
Hess J, Angel P and Schorpp-Kistner M:
AP-1 subunits: Quarrel and harmony among siblings. J Cell Sci.
117:5965–5973. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ye N, Ding Y, Wild C, Shen Q and Zhou J:
Small molecule inhibitors targeting activator protein 1 (AP-1). J
Med Chem. 57:6930–6948. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mahner S, Baasch C, Schwarz J, Hein S,
Wölber L, Jänicke F and Milde-Langosch K: C-Fos expression is a
molecular predictor of progression and survival in epithelial
ovarian carcinoma. Br J Cancer. 99:1269–1275. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bamberger AM, Milde-Langosch K, Rössing E,
Goemann C and Löning T: Expression pattern of the AP-1 family in
endometrial cancer: Correlations with cell cycle regulators. J
Cancer Res Clin Oncology. 127:545–550. 2001. View Article : Google Scholar
|
|
16
|
Gamberi G, Benassi MS, Bohling T,
Ragazzini P, Molendini L, Sollazzo MR, Pompetti F, Merli M,
Magagnoli G, Balladelli A and Picci P: C-myc and c-fos in human
osteosarcoma: Prognostic value of mRNA and protein expression.
Oncology. 55:556–563. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Szabo E, Riffe ME, Steinberg SM, Birrer MJ
and Linnoila RI: Altered cJUN expression: An early event in human
lung carcinogenesis. Cancer Res. 56:305–315. 1996.PubMed/NCBI
|
|
18
|
Vleugel MM, Greijer AE, Bos R, van der
Wall E and van Diest PJ: c-Jun activation is associated with
proliferation and angiogenesis in invasive breast cancer. Human
Pathol. 37:668–674. 2006. View Article : Google Scholar
|
|
19
|
Gromova I, Gromov P and Celis JE: bc10: A
novel human bladder cancer-associated protein with a conserved
genomic structure downregulated in invasive cancer. Int J Cancer.
98:539–546. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Moreira JM, Gromov P and Celis JE:
Expression of the tumor suppressor protein 14-3-3 sigma is
down-regulated in invasive transitional cell carcinomas of the
urinary bladder undergoing epithelial-to-mesenchymal transition.
Mol Cell Proteomics. 3:410–419. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Han ZD, He HC, Bi XC, Qin WJ, Dai QS, Zou
J, Ye YK, Liang YX, Zeng GH, Zhu G, et al: Expression and clinical
significance of CD147 in genitourinary carcinomas. J Surg Res.
160:260–267. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhong WD, Chen QB, Ye YK, Han ZD, Bi XC,
Dai QS, Liang YX, Zeng GH, Wang YS, Zhu G, et al: Extracellular
matrix metalloproteinase inducer expression has an impact on
survival in human bladder cancer. Cancer Epidemiol. 34:478–482.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kong LM, Liao CG, Zhang Y, Xu J, Li Y,
Huang W, Zhang Y, Bian H and Chen ZN: A regulatory loop involving
miR-22, Sp1, and c-Myc modulates CD147 expression in breast cancer
invasion and metastasis. Cancer Res. 74:3764–3778. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zheng HC, Takahashi H, Murai Y, Cui ZG,
Nomoto K, Miwa S, Tsuneyama K and Takano Y: Upregulated
EMMPRIN/CD147 might contribute to growth and angiogenesis of
gastric carcinoma: A good marker for local invasion and prognosis.
Br J Cancer. 95:1371–1378. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liang YX, He HC, Han ZD, Bi XC, Dai QS, Ye
YK, Qin WJ, Zeng GH, Zhu G, Xu CL and Zhong WD: CD147 and VEGF
expression in advanced renal cell carcinoma and their prognostic
value. Cancer Invest. 27:788–793. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ishibashi Y, Matsumoto T, Niwa M, Suzuki
Y, Omura N, Hanyu N, Nakada K, Yanaga K, Yamada K, Ohkawa K, et al:
CD147 and matrix metalloproteinase-2 protein expression as
significant prognostic factors in esophageal squamous cell
carcinoma. Cancer. 101:1994–2000. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Riethdorf S, Reimers N, Assmann V,
Kornfeld JW, Terracciano L, Sauter G and Pantel K: High incidence
of EMMPRIN expression in human tumors. Int J Cancer. 119:1800–1810.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhong WD, Han ZD, He HC, Bi XC, Dai QS,
Zhu G, Ye YK, Liang YX, Qin WJ, Zhang Z, et al: CD147, MMP-1, MMP-2
and MMP-9 protein expression as significant prognostic factors in
human prostate cancer. Oncology. 75:230–236. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yu W, Liu J, Xiong X, Ai Y and Wang H:
Expression of MMP9 and CD147 in invasive squamous cell carcinoma of
the uterine cervix and their implication. Pathol Res Pract.
205:709–715. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hagemann T, Wilson J, Kulbe H, Li NF,
Leinster DA, Charles K, Klemm F, Pukrop T, Binder C and Balkwill
FR: Macrophages induce invasiveness of epithelial cancer cells via
NF-kappa B and JNK. J Immunol. 175:1197–1205. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bossis G, Malnou CE, Farras R,
Andermarcher E, Hipskind R, Rodriguez M, Schmidt D, Muller S,
Jariel-Encontre I and Piechaczyk M: Down-regulation of c-Fos/c-Jun
AP-1 dimer activity by sumoylation. Mol Cell Biol. 25:6964–6979.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ramos-Nino ME and Littenberg B: A novel
combination: Ranpirnase and rosiglitazone induce a synergistic
apoptotic effect by down-regulating Fra-1 and Survivin in cancer
cells. Mol Cancer Ther. 7:1871–1879. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang CW, Lee YZ, Hsu HY, Wu CM, Chang HY,
Chao YS and Lee SJ: c-Jun-mediated anticancer mechanisms of
tylophorine. Carcinogenesis. 34:1304–1314. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Eferl R, Ricci R, Kenner L, Zenz R, David
JP, Rath M and Wagner EF: Liver tumor development. c-Jun
antagonizes the proapoptotic activity of p53. Cell. 112:181–192.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Briggs J, Chamboredon S, Castellazzi M,
Kerry JA and Bos TJ: Transcriptional upregulation of SPARC, in
response to c-Jun overexpression, contributes to increased motility
and invasion of MCF7 breast cancer cells. Oncogene. 21:7077–7091.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Smith LM, Wise SC, Hendricks DT, Sabichi
AL, Bos T, Reddy P, Brown PH and Birrer MJ: cJun overexpression in
MCF-7 breast cancer cells produces a tumorigenic, invasive and
hormone resistant phenotype. Oncogene. 18:6063–6070. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhao S, Ma W, Zhang M, Tang D, Shi Q, Xu
S, Zhang X, Liu Y, Song Y, Liu L and Zhang Q: High expression of
CD147 and MMP-9 is correlated with poor prognosis of
triple-negative breast cancer (TNBC) patients. Med Oncol.
30:3352013. View Article : Google Scholar : PubMed/NCBI
|
